Should You Buy Pacific Biosciences Stock Now?
Earlier this month we dissected the ongoing battle between investor activist Carl Icahn and the second-biggest holding in our Nanalyze Disruptive Tech Portfolio – Illumina (ILMN). The latest round just came to an end on May 25 when shareholders approved one of Icahn’s three hand-picked nominees for the gene-sequencing company’s board of directors, ousting the […]